1) Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS 2001; 15:1389098.
2) Kosmiski L, Kuritzkes D, Lichtenstein KA, et al. Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS 2001; 15:1-8.
3) Kosmiski L, Kuritzkes D, Lichtenstein KA, Eckel R. Adipocyte-derived hormone levels in HIV lipodystrophy. Antivir Ther 2003; 8(1):9-15.
4) Lichtenstein KA, Delaney KM, Armon C, et al. Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1 infected patients. JAIDS. 2003; 32:48-56.
5) Anderson PL, Kakuda TN, Lichtenstein KL. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse transcriptase inhibitors and its relationship to clinical toxicities. Clin Infect Dis. 2004;38:743-53.
6) Holmberg SD, Palella FJ, Lichtenstein KA, Havlir DV. The case for earlier treatment of HIV infection. Clin Infect Dis. 2004; 39:1699-704.
7) Lichtenstein KA, Armon C, Moorman AC, et al. A 7-year longitudinal analysis of IL-2 in patients treated with highly active antiretroviral therapy. AIDS. 2004;18,17:4-6.
8) Lichtenstein KA, Armon C, Baron A, et al. Modification of the incidence of drug-associated symmetrical peripheral neuropathy by host and disease factors in the HIV Outpatient cohort. Clin Infec Dis. 2005; 40:148-157.
9) Lichtenstein KA. Redefining lipodystrophy syndrome: risks and impact on clinical decision making. JAIDS. 2005; 39(4): 395-400.